- recruitingPhase I and Phase II (Integrated)- First administration to humans
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
This clinical trial is testing a new cancer medicine called GEN1042 in people for the first time. Doctors want to find safe doses for adults with solid tumours. They will also check if GEN1042, given alone or with standard cancer medicines, helps shrink or stop cancer growth.
France · Italy · Germany - recruitingPhase I and Phase II (Integrated)- First administration to humans
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors
This study is testing a new medicine, GEN1047, in women with different types of cancer. We want to find out if it's safe, what the right dose is, and if it helps shrink tumours. It's an early-stage study to see how the medicine works in people for the first time.
Denmark · Belgium · Netherlands - recruitingPhase I and Phase II (Integrated)- First administration to humans
First-in-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of GEN1078 in Subjects With Malignant Solid Tumors
This early-stage study is testing a new drug called GEN1078 for adults with different types of solid cancers. Researchers want to find out if it's safe, what dose works best, and if it can shrink tumors or stop them from growing.
Denmark · Spain - recruitingPhase I and Phase II (Integrated)- First administration to humans
First-in-Human, Open-label, Dose-Escalation Trial with Expansion Cohorts to Evaluate the Safety of GEN1053 as Monotherapy and in Combination With an Immunomodulator in Subjects with Malignant Solid Tumors
This study is testing a new medicine called HexaBody-CD27 for people with solid tumours that have spread. It's looking at how safe the medicine is, how much to give, and if it can help shrink tumours. It's an early-stage study to understand this new treatment better.
Spain - recruitingPhase I and Phase II (Integrated)- First administration to humans
First-In-Human, Open-Label, Dose Escalation Trial with Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects with Malignant Solid Tumors.
This study is testing a new medicine, GEN1055, for various cancers. It's looking at how safe it is, what side effects it causes, and how well it works, both on its own and with other cancer treatments like Pemetrexed and Pembrolizumab.
Spain